Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial |
HERBST RS, LANCET |
2016 |
37 |
2,399 |
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial |
RITTMEYER A, LANCET |
2017 |
27 |
1,426 |
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial |
FEHRENBACHER L, LANCET |
2016 |
18 |
1,151 |
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial |
WEBER JS, LANCET ONCOL |
2015 |
13 |
1,331 |
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-years overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial |
HODI FS, LANCET ONCOL |
2016 |
11 |
392 |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538–12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial |
KANG YK, LANCET |
2017 |
11 |
431 |
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial |
RIBAS A, LANCET ONCOL |
2015 |
9 |
791 |
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study |
LANGER CJ, LANCET ONCOL |
2016 |
8 |
633 |
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial |
BRAHMER JR, LANCET ONCOL |
2017 |
7 |
81 |
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized phase II Trial |
MOTZER RJ, J CLIN ONCOL |
2015 |
6 |
556 |
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial |
CELLA D, LANCET ONCOL |
2016 |
6 |
106 |
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) |
SCHACHTER J, LANCET |
2017 |
5 |
331 |
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-years outcomes of a multicentre, randomised, phase 3 trial |
HODI FS, LANCET ONCOL |
2018 |
5 |
230 |
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma |
MCDERMOTT DF, NAT MED |
2018 |
5 |
169 |
Nivolumab vs. investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-years long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression |
FERRIS RL, ORAL ONCOL |
2018 |
5 |
108 |